Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 3/20 | 0.44 |
| ▸ | BCR | P11274 | 2/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.40 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.39 |
| ▸ | DAGLB | Q8NCG7 | 1/20 | 0.38 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19780650 | 0.83 | FASN (0.47) | ABL1BCRSLC6A7TRPV1 | |
| SCHEMBL9001893 | 0.80 | NPSR1 (0.54) | — | |
| SCHEMBL18573293 | 0.77 | ABL1 (0.48) | ABL1BCRDHODHSLC6A7TRPV1 | |
| SCHEMBL6356563 | 0.73 | KDM4E (0.50) | ABL1BCRDHODHCYP2A6 | |
| SCHEMBL21012595 | 0.73 | KDM4E (0.50) | ABL1BCRDHODHCYP2A6 | |
| SCHEMBL19780959 | 0.71 | ELANE (0.47) | ABL1BCRDHODHSLC6A7KDM2B | |
| SCHEMBL21477385 | 0.71 | PTPN2 (0.53) | ABL1TRPV1 | |
| SCHEMBL28214265 | 0.71 | CYP2A6 (0.57) | DHODHSLC6A7CYP2A6 | |
| SCHEMBL20427797 | 0.71 | CYP1A2 (0.47) | DHODHCYP2A6 | |
| SCHEMBL9001849 | 0.71 | HTT (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322826-A1 | METAL COMPLEXES | UDC IRELAND LIMITED (IE) | 2023-10-12 | — | — | US | disclosed |
| US-20230322826-A1 | METAL COMPLEXES | UDC IRELAND LIMITED (IE) | 2023-10-12 | — | — | US | disclosed |
| US-11713332-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2023-08-01 | — | — | US | disclosed |
| US-11713332-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2023-08-01 | — | — | US | disclosed |
| EP-3484868-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2020-11-25 | — | — | EP | disclosed |
| US-20190315787-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-10-17 | — | — | US | disclosed |
| WO-2018011186-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315787-A1 | METAL COMPLEXES | AP1M1, SOD1, AP3M1 | ABL1 2641/4885BCR 4083/4885DHODH 3981/4885 |
| US-11713332-B2 | Metal complexes | AP1M1, SOD1, AP3M1 | ABL1 2641/4885BCR 4083/4885DHODH 3981/4885 |
| US-20230322826-A1 | METAL COMPLEXES | AP1M1, SOD1, AP3M1 | ABL1 2641/4885BCR 4083/4885DHODH 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.